Stevenson L.LI-MIN HUANGBerlaimont V.Folschweiller N.2021-06-242021-06-2420170022-1899https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031685425&doi=10.1093%2finfdis%2fjix365&partnerID=40&md5=c9d3288a5a4386ce69292152e6be6943https://scholars.lib.ntu.edu.tw/handle/123456789/566399[SDGs]SDG3Wart virus vaccine; vaccine; appendicitis; autoimmune disease; celiac disease; clinical outcome; clinical trial (topic); cohort analysis; drug safety; human; immunogenicity; incidence; knee pain; Letter; observational study; postmarketing surveillance; priority journal; retrospective study; risk benefit analysis; synovitis; systemic lupus erythematosus; vaccination; Humans; Vaccinesletter10.1093/infdis/jix365289344402-s2.0-85031685425